A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3045697 After Single Oral Dosing in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2013
At a glance
- Drugs LY 3045697 (Primary)
- Indications Heart failure; Hypertension
- Focus Adverse reactions
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 May 2013 Planned end date changed from 1 Aug 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 09 May 2013 Planned End Date changed from 1 May 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.